Search clinical trials for: Gemcitabine Lapatinib

Total 4457 results

Henan Cancer Hospital

Unknown

Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer

Advanced Gastric Cancer
GUO WEI

Completed

Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy

Osteosarcoma | Metastasis

China
Tianjin Medical University Cancer Institute and...
Zhejiang Cancer Hospital; Fudan University; Liaoning Tumor Hospital & Institute; Gansu Cancer Hospital

Unknown

Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy

Soft Tissue Sarcoma, Adult, Stage II

China
Hebei Medical University Fourth Hospital

Recruiting

Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor

Advanced Solid Tumor

China
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
Sunshine Lake Pharma Co., Ltd.

Terminated

Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

Pancreatic Cancer

China
West China Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC

Lung Cancer | Non Small Cell Lung Cancer | Apatinib | Combination Chemotherapy

China
National Cancer Institute (NCI)

Completed

Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Adult Primary Hepatocellular...

United States
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Terminated

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

Leukemia

United States
Frederick R. Ueland, M.D.
National Cancer Institute (NCI)

Active, not recruiting

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

Ovarian Cancer

United States
GlaxoSmithKline

Withdrawn

A Phase I Study Of Oral Topotecan And Lapatinib In Subjects With Advanced Solid Tumors

Advanced Solid Tumors

United States
GlaxoSmithKline

Completed

Lapatinib in Combination With Vinorelbine

Cancer

Turkey
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline; Genentech, Inc.; Susan G. Komen Breast Cancer Foundation

Completed

Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib

Breast Neoplasms

United States
Novartis Pharmaceuticals

Completed

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Metastases, Brain

Spain, Hungary, Poland, Germany, Italy, Russian Federation, Sweden, United Kingdom, Thailand, United States, Belgium, France, Greece, Denmark
GlaxoSmithKline

Completed

Physician Liver Function Test (LFT) Monitoring for Tykerb Pts

Cancer
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE) (OAIE)

Toxicity | Effect of Drug | Drug

China
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
Henan Cancer Hospital

Recruiting

Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer (CAMERA)

Small Cell Lung Carcinoma

China
Sun Yat-sen University

Recruiting

Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma

Neoadjuvant Therapy | Apatinib | Carilizumab | Recurrent High-Grade Glioma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Relapsed Ovarian Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

Colorectal Cancer

China
Shanghai Zhongshan Hospital

Unknown

Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Gastric Cancer | Chemotherapy Effect | Chemotherapeutic Toxicity

China
Henan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.

Non-Small Cell Lung Carcinoma

India
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

A Bioequivalence Study of Dasatinib Tablet

Leukemia, Myelogenous, Chronic

China
Peking University People's Hospital
Peking University Shougang Hospital; Jiangsu HengRui Medicine Co.

Recruiting

Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma (AIEO)

Effect of Drug | Toxicity, Drug

China
Sun Yat-sen University

Recruiting

Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma (C-couple)

Hepatocellular Carcinoma

China
Bukwang Pharmaceutical

Completed

A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment

Gastric Cancer

Korea, Republic of
Beijing Tsinghua Chang Gung Hospital

Unknown

Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer

Hepatocellular Carcinoma
Fujian Cancer Hospital

Unknown

Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens (ASGARD)

Advanced Metastatic Gastric Cancer
Guilin Medical University, China
Wuzhou Red Cross Hospital; Guangxi Naxishan Hospital; National Hospital of Guangxi...

Unknown

Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
The Affiliated Hospital of the Chinese Academy...

Unknown

Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer

Hepatocellular Carcinoma | Gastric Cancer

China
Tongji University

Unknown

The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Unknown

A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy

Gastric Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Harbin Medical University

Recruiting

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Gastrointestinal Cancer | Immunotherapy | Targeted Therapy

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS

Sarcoma
Henan Cancer Hospital

Unknown

Apatinib Plus SHR1210 in Advanced Mucosal Melanoma

Advanced Cancer | Mucosal Melanoma | Apatinib | SHR-1210

China
Beijing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

China
Shanxi Province Cancer Hospital

Unknown

Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer

Brain Metastases
Zhejiang Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer

Gastric Cancer

China
Korean Breast Cancer Study Group

Unknown

Neoadjuvant Chemotherapy With Docetaxel and Gemcitabine in Locally Advanced Breast Cancer (NeoTG)

Breast Cancer Stage II | Breast Cancer Stage III

Korea, Republic of
GlaxoSmithKline

Terminated

Lapatinib + Vinorelbine in ErbB2 Overexpressing, First or Second Line Metastatic Breast Cancer Subjects

Neoplasms, Breast

United States
Novartis Pharmaceuticals

Completed

Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC

Neoplasms, Breast

United States
GlaxoSmithKline

Completed

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

Neoplasms, Breast

Korea, Republic of, Canada, United States
National Cancer Institute (NCI)

Terminated

Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive

United States
Cancer Institute and Hospital, Chinese Academy...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR

Lung Adenocarcinoma

Search clinical trials for: Gemcitabine Lapatinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations